Market cap
$211 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.9
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | -- | -- | -- | -- | -- |
| Net Profit | 18.38 | -26.66 | 2.95 | 10.03 | -189.87 |
| EPS | 37.89 | 14.62 | 13.86 | 17.35 | -- |
| Book Value | -- | -- | -35.89 | -29.04 | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -- | -- | -- | -- | -- |
| Net Margin
| -- | -- | -- | -- | -- |
| Return on equity
| -53.56 | -55.96 | -56.25 | -52.14 | -49.69 |
| Return on Capital
| -53.55 | -55.96 | -- | -52.14 | -49.69 |
| Return on Assets
| -47.93 | -50.99 | -29.68 | -45.67 | -44.47 |
| Debt to Equity (x)
| -- | -- | 0.00 | -- | -- |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AN2 Therapeutics Inc (ANTX)
|
--
|
-52.14
|
-49.69
|
-58.81
|
-52.72
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-56.25
Lower than Peers by 15.85
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AN2 Therapeutics Inc (ANTX)
|
-56.25
|
-52.14
|
-49.69
|
-58.83
|
-52.73
|
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
ROA
-29.68
Higher than Peers by 1.30
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AN2 Therapeutics Inc (ANTX)
|
-29.68
|
-45.67
|
-44.47
|
-53.65
|
-49.41
|
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
EBIT Growth
--
--
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AN2 Therapeutics Inc (ANTX)
|
--
|
--
|
20.72
|
-53.17
|
-95.89
|
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
Net Profit Growth
2.95
Higher than Peers by 10.25
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AN2 Therapeutics Inc (ANTX)
|
2.95
|
31.46
|
20.72
|
-56.09
|
-93.12
|
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
EPS Growth
13.86
Lower than Peers by 0.79
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AN2 Therapeutics Inc (ANTX)
|
13.86
|
0.32
|
0.21
|
-0.02
|
-0.81
|
|
Peer Median
|
14.65
|
--
|
--
|
--
|
--
|
Book Value Growth
-25.66
Lower than Peers by 15.48
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AN2 Therapeutics Inc (ANTX)
|
-25.66
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.18
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AN2 Therapeutics Inc (ANTX)
|
--
|
--
|
--
|
--
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AN2 Therapeutics Inc (ANTX)
|
--
|
--
|
--
|
--
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
14.32
Higher than Peers by 8.51
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AN2 Therapeutics Inc (ANTX)
|
14.32
|
6.87
|
8.43
|
7.87
|
13.72
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
14.32
Higher than Peers by 8.63
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AN2 Therapeutics Inc (ANTX)
|
14.32
|
--
|
--
|
--
|
--
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AN2 Therapeutics Inc (ANTX)
|
--
|
--
|
--
|
--
|
-82.22
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Asset Turnover
--
--
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AN2 Therapeutics Inc (ANTX)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AN2 Therapeutics Inc (ANTX)
|
--
|
--
|
--
|
--
|
7,554.03
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AN2 Therapeutics Inc (ANTX)
|
--
|
-0.98
|
-0.80
|
-9.41
|
-4.46
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
2.86
Lower than Peers by 2.32
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AN2 Therapeutics Inc (ANTX)
|
2.86
|
0.65
|
0.50
|
4.89
|
1.94
|
|
Peer Median
|
5.18
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AN2 Therapeutics Inc (ANTX)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-2.11
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AN2 Therapeutics Inc (ANTX)
|
-2.11
|
0.67
|
-13.11
|
102.38
|
-2.05
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
211
Higher than Peers by 65
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
AN2 Therapeutics Inc (ANTX)
|
211
|
--
|
--
|
--
|
--
|
|
Peer Median
|
146
|
--
|
--
|
--
|
--
|